Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „Lenvima“
Suchtreffer
Begriffe & Kennungen
Lenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), hypocalcaemia was reported in 3.9% of lenvatinib plus pembrolizuma
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), hypothyroidism was reported in 68.2% of lenvatinib plus pembrolizu
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), proteinuria was reported in 29.6% of lenvatinib plus pembrolizumab
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), there was one event of PRES (Grade 1) in the lenvatinib plus pembr
Eintrag öffnenLenvima · 4.8 · In the combination dose-finding cohort of Study 207, the most frequently (≥50%) reported adverse drug reaction
Eintrag öffnenLenvima · 4.8 · In the paediatric Studies 207, 216, 230, and 231 (see section 5.1), the overall safety profile of lenvatinib a
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), 5.0% of patients developed renal failure and 1.9% devel
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), 88% of all patients had a baseline TSH level less than
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), QT/QTc interval prolongation was reported in 8.8% of le
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), arterial thromboembolic events were reported in 5.4% of
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), decreased ejection fraction/cardiac failure was reporte
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), diarrhoea was reported in 67.4% of patients in the lenv
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), events of gastrointestinal perforation or fistula were
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), haemorrhage was reported in 34.9% (1.9% were Grade ≥ 3)
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), hypertension (including hypertension, hypertensive cris
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), hypocalcaemia was reported in 12.6% of lenvatinib-treat
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), proteinuria was reported in 33.7% of lenvatinib- treate
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), the most commonly reported liver-related adverse reacti
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), there was 1 event of PRES (Grade 2) in the lenvatinib-t
Eintrag öffnenLenvima · 4.8 · In the single-agent dose-finding cohort of Study 207, the most frequently (≥40%) reported adverse drug reactio
Eintrag öffnen